Welcome to our dedicated page for Werewolf Therapeutics news (Ticker: HOWL), a resource for investors and traders seeking the latest updates and insights on Werewolf Therapeutics stock.
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) is a clinical-stage biopharmaceutical company pioneering conditionally activated immunotherapies for cancer treatment. This news hub provides investors and industry observers with essential updates on the company’s innovative pipeline, including its INDUKINE molecules WTX-330 and WTX-124 developed through the proprietary PREDATOR platform.
Access real-time announcements covering clinical trial progress, regulatory milestones, financial results, and strategic partnerships. Our curated collection ensures you stay informed about developments in immuno-oncology therapies designed to activate only within tumor microenvironments – a breakthrough approach aiming to improve safety profiles compared to traditional cytokine treatments.
Key updates include phase 1/2 trial data readouts, IND applications, collaboration agreements, and peer-reviewed research publications. All content is vetted for relevance to investment analysis and therapeutic advancement in solid tumors and immune-mediated diseases.
Bookmark this page for streamlined tracking of HOWL’s scientific and corporate developments. Combine our news feed with Stock Titan’s financial tools to monitor this innovator’s progress in redefining cancer immunotherapy.
Werewolf Therapeutics (Nasdaq: HOWL) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Positive data from WTX-124 Phase 1/1b trial presented at ASCO, showing clinical activity and tolerability.
2. Encouraging signs of clinical activity for WTX-330 Phase 1 trial at tolerable doses.
3. Cash position of $135.3 million as of June 30, 2024, expected to fund operations through Q1 2026.
4. Q2 2024 net loss of $17.2 million, compared to $5.1 million in Q2 2023.
5. Collaboration revenue decreased to $1.1 million in Q2 2024 from $8.1 million in Q2 2023.
6. R&D expenses increased to $15.3 million in Q2 2024 from $9.6 million in Q2 2023.
Werewolf Therapeutics reveals initial safety and efficacy data from its ongoing Phase 1 clinical trial of WTX-330. The trial involves patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma. The data show WTX-330 achieved therapeutically relevant exposure levels of IL-12 prodrug with improved tolerability compared to historical data. One metastatic melanoma patient showed an unconfirmed partial response, and two colorectal cancer patients achieved stable disease. Mild to moderate treatment-related toxicities were observed, with no Grade 4 or 5 adverse events. An expanded Phase 1 program is now open, with further results anticipated in Q4 2024.
Werewolf Therapeutics has announced new data from their Phase 1/1b trial of WTX-124, an IL-2 INDUKINETM molecule, in patients with solid tumors. The data, presented at ASCO 2024, highlight WTX-124's clinical activity and tolerability, both as a monotherapy and in combination with pembrolizumab. Three objective responses were noted, including one complete response, and the treatment was generally well-tolerated. The company has selected an 18 mg dose of WTX-124 monotherapy for expansion and opened three new trial arms. Additionally, WTX-124 showed enhanced immune activation in combination with pembrolizumab. A webcast to discuss these findings will be held on June 3, 2024.
Werewolf Therapeutics, an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics to stimulate the body's immune system for cancer treatment, announced its participation at the Jefferies Global Healthcare Conference.
Daniel J. Hicklin, Ph.D., President and CEO, and Randi Isaacs, M.D., Chief Medical Officer, will join a fireside chat at 1:00 PM ET on June 6, 2024. The conference will be held from June 4-6 in New York City.
A live webcast link for the event will be available on Werewolf's investor relations webpage, with an archived replay accessible for 90 days post-event.
Werewolf Therapeutics announced the presentation of updated clinical data from its Phase 1/1b trial of WTX-124, both as monotherapy and in combination with pembrolizumab, at the 2024 ASCO Annual Meeting. The data, current as of January 28, 2024, and updated until May 1, 2024, shows that WTX-124 is well-tolerated and clinically active in patients with advanced or metastatic solid tumors who have relapsed after checkpoint inhibitor therapy.
Preliminary combination data with pembrolizumab indicates similar tolerability to monotherapy. Werewolf will host a webcast on June 3, 2024, to discuss the results in detail. This Phase 1/1b trial is evaluating the IL-2 INDUKINE™ molecule, aiming to address unmet medical needs in difficult-to-treat cancers.
Werewolf Therapeutics, Inc. reports Q1 2024 financial results and business update. The company focuses on WTX-124 and WTX-330 clinical trials, with promising data expected. They showcase the PREDATOR platform potential in immunology-based diseases. Werewolf extends its cash runway till Q1 2026. Recent achievements include FDA alignment on a manufacturing process and entering a funding agreement with K2 HealthVentures. Financially, the company maintains a solid cash position, with collaboration revenue and R&D expenses on track.
FAQ
What is the current stock price of Werewolf Therapeutics (HOWL)?
What is the market cap of Werewolf Therapeutics (HOWL)?
